Xenetic Biosciences (XBIO) Names Former Dana-Farber CEO Benz as Director
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- S&P 500 ends up slightly with boost from financials; Netflix up late
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- La Quinta Holdings (LQ) Gains on Plan to Split in Two
- After-Hours Stock Movers 01/18: (OCLR) (CSX) (NFLX) Higher; (AMDA) (RCII) (ZYNE) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Xenetic Biosciences, Inc. (Nasdaq: XBIO) announced that it has appointed Edward J. Benz, Jr., M.D., to the Company’s Board of Directors.
Dr. Benz is a renowned expert in blood disorders and is board certified in both hematology and internal medicine. He is an active clinical hematologist and a National Institutes of Health (NIH) funded researcher with a focus on the molecular basis and genetics around inherited blood disorders. Prior to joining the Xenetic Board, Dr. Benz served as President and CEO Emeritus of Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine and Professor of Genetics at Harvard Medical School. During Dr. Benz’s tenure at Dana-Farber, the institute experienced exponential growth, including an increase of fund-raising to more than $200 million a year from a network of 300,000 donors, a tripling of the number of patients seeking treatment, and a growth in revenues from $265 million to more than $1 billion.
Commenting on the appointment, Scott Maguire, CEO of Xenetic Biosciences, stated, “We are incredibly honored to welcome Dr. Benz to the Company’s Board of Directors. We fully believe that Dr. Benz’s leadership in oncology will bring an immense wealth of knowledge and add incredible perspective to the Company during a critical growth phase for Xenetic as we continue to advance our cancer drug candidate pipeline. With our recent uplist to Nasdaq and this key appointment, I believe we are poised for continued momentum that will increase through the remainder of this year and the next."
Prior to his role at Dana-Farber, Dr. Benz served as the chairman for the Department of Medicine and Sir William Osler Professor of Medicine at Johns Hopkins University School of Medicine, as well as physician-in-chief at Johns Hopkins Hospital. Dr. Benz has also served as President of the American Society of Hematology, the Association of American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Society, and the Friends of the National Institute of Nursing Research. Over the course of his career, Dr. Benz has authored more than 300 articles, books, reviews and abstracts and has received numerous awards including the Margaret L. Kripke Legend Award, the American Society of Hematology Mentoring Award in Basic Science, and Leon Resnick Awards for Research.
Dr. Edward Benz Jr. commented, “I am excited to be joining the Xenetic team at such an important time for the Company. I believe that Xenetic continues to take the necessary steps to advance the Company, its partnerships and product candidates towards commercialization in areas of significant unmet need.”
Dr. Benz earned his bachelor’s degree from Princeton University. He received his Doctor of Medicine from Harvard Medical School, completed his medical school thesis at Boston Children’s Hospital and completed his training at the National Institutes of Health, Yale University School of Medicine and Brigham and Women’s Hospital in Boston, MA.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Summit Hotel Properties (INN) Appoints Daniel Hansen as Chairman of the Board
- US Foods (USFD) Names Andrew Iacobucci as CMO
- ServiceMaster Global Holdings (SERV) CFO to Alan Haughie Retire; Anthony DiLucente to Succeed; Reaffirms FY Guidance
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!